Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline and Crucell to develop malaria vaccine

GlaxoSmithKline and Crucell to develop malaria vaccine

9th April 2010

GlaxoSmithKline is to collaborate with biopharmaceutical company Crucell on the development of a new vaccine for malaria.

This collaboration will see GlaxoSmithKline combine its candidate therapy RTS,S/AS with Crucell’s Advac technology in order to create a potentially promising second generation vaccine candidate.

The partnership has been agreed based on promising results from a combination study of the two components, which demonstrated an enhanced immune response compared to either therapy used on its own.

Ronald Brus, chief executive officer at Crucell, stated that this treatment could play a key role in combating a disease which remains one of the world’s top three killers.

He said: “I am confident a partnership of this kind will allow us to take a vital step towards our goal of bringing meaningful innovation to global health.”

Last week, the company partnered with Isis Pharmaceuticals to create new treatments for rare and infectious diseases using RNA interference technology.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.